EGCG Suppressed Activation of Hepatic Stellate Cells by Regulating the PLCE1/IP₃/Ca²⁺ Pathway

Investigators suggested that oral administration of (-)-Epigallocatechin-3-O-gallate (EGCG) at a dosage of 200 mg/kg/day for a duration of four weeks exhibits significant therapeutic potential in a murine model of liver fibrosis induced by CCl4.